Rhabdomyolysis and AKI Following Atorvastatin-Gemfibrozil Rhabdomyolysis and AKI Following Atorvastatin-Gemfibrozil

This case report demonstrates that severe rhabdomyolysis due to statins with or without fibrates may occur with few clinical symptoms and signs, even many weeks after discontinuation of therapy.Journal of Medical Case Reports
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Related Links:

Studies have demonstrated that statins reduce cardiovascular risk in men and women, but the effectiveness of statins among low-risk women continues to be contentious. One reason is that the number of women enrolled in statin trials has been small relative to men, limiting statistical inferences. Also, for any given age women have a lower absolute risk of cardiovascular disease when compared to men. When absolute benefit is low, the risk of adverse effects becomes more important. Myopathy and rhabdomyolysis are rare but established side-effects of statin therapy, and concern is growing that statins could increase the risk o...
Source: Maturitas - Category: Primary Care Authors: Tags: INV24 Source Type: research
Conclusions: Muscle damage induced by interaction between FA and statin is a potentially life-threatening complication, leading to contraindication of this association in France. This is to be reminded especially because FA is about to get FDA approval and should soon be available in the United States.
Source: American Journal of Therapeutics - Category: Drugs & Pharmacology Tags: Systematic Reviews Source Type: research
Authors: Pennisi M, Di Bartolo G, Malaguarnera G, Bella R, Lanza G, Malaguarnera M Abstract Introduction: Statin-associated muscle symptoms are common side effects of statin therapy. These symptoms include myopathy, myalgia, and rhabdomyolysis. Vitamin D has been associated with musculoskeletal health; thus, its deficiency may produce detrimental effects in this tissue. Indeed, one symptom of vitamin D deficiency is myalgia, and the normalization of low vitamin D levels can relieve it. Patients and Methods: This cross-sectional study examined 1210 statin-treated patients to assess vitamin D status. These patien...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Publication date: Available online 12 March 2019Source: Pharmacological ResearchAuthor(s): Jamal Bouitbir, Gerda M. Sanvee, Miljenko V. Panajatovic, François Singh, Stephan KrähenbühlAbstractStatins lower the serum low-density lipoprotein cholesterol and prevent cardiovascular events by inhibiting 3-hydroxy-3-methyl-glutaryl-CoA reductase. Although the safety of statins is documented, many patients ingesting statins may suffer from skeletal muscle-associated symptoms (SAMS). Importantly, SAMS are a common reason for stopping the treatment with statins. Statin-associated muscular symptoms include fatigue, w...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
In this study, a rhabdomyolysis mouse model was established by coadministration of the clinically using statin and fibrate. This mouse model may be useful to identify drugs that have high risk for rhabdomyolysis. PMID: 30853469 [PubMed - as supplied by publisher]
Source: Toxicology Letters - Category: Toxicology Authors: Tags: Toxicol Lett Source Type: research
Conclusion: The three-parameter model assumes a common drug–drug interaction effect, whereas the saturated model is useful for identifying potential effect heterogeneity or differential confounding across strata. Restriction to certain strata or use of an active comparator may be necessary in the presence of within-person confounding.
Source: Epidemiology - Category: Epidemiology Tags: Pharmacoepidemiology Source Type: research
In this study, the GSH‐depletion treatment established an acute kidney injury mouse model due t o Mb release from the damaged skeletal muscle. This mouse model would be useful for predicting potential acute kidney injury risks in non‐clinical drug development.
Source: Journal of Applied Toxicology - Category: Toxicology Authors: Tags: RESEARCH ARTICLE Source Type: research
Publication date: Available online 6 February 2019Source: Joint Bone SpineAuthor(s): Anne TournadreAbstractStatin-associated muscle symptoms (SAMSs) vary considerably in frequency and severity, with a spectrum extending from myalgia with normal creatine kinase (CK) levels or asymptomatic hyperCKemia to potentially life-threatening rhabdomyolysis and necrotizing autoimmune myopathy. Myalgia with CK elevation is the most common presentation. Onset is usually within 1 month after statin initiation or dosage intensification, and the symptoms can be expected to resolve within a few weeks after treatment discontinuation. The mec...
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research
Conclusion: The three-parameter model assumes a common drug–drug interaction effect, whereas the saturated model is useful for identifying potential effect heterogeneity or differential confounding across strata. Restriction to certain strata or use of an active comparator may be necessary in the presence of within-person confounding.
Source: Epidemiology - Category: Epidemiology Tags: Pharmacoepidemiology Source Type: research
To the Editor: Statins are among the most commonly prescribed medications in the world. Myalgia is frequently reported in up to 25% of users,1 and more serious adverse effects on muscle such as rhabdomyolysis are seen in 0.04% to 0.2% of users.1 Muscle rupture has also been reported.2 Furthermore, subgroups such as professional athletes appear to be especially intolerant to statin drugs.3 Dietary interventions such as the portfolio diet have also been reported to cause marked reductions in cholesterol.
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Tags: Letter to the editor Source Type: research
More News: Atorvastatin Calcium | Cholesterol | Gemfibrozil | Health | Lipitor | Primary Care | Rhabdomyolysis | Statin Therapy | Zivast